Multiple sclerosis impact on pregnancy: An update on management issues

  • Ahmadreza Badali Medical School, Tabriz University of Medical Sciences, Tabriz, Iran
  • Rahil GhorbaniNia Faculty of Management and Medical Information, Kerman University of Medical Sciences, Kerman, Iran https://orcid.org/0000-0002-3153-0544
  • Shima Mohammadian Department of Gynecology Oncology, Kamali Teaching Hospital, Alborz University of Medical Sciences, Karaj, Iran
  • Sahar poudineh School of Medicine, Mashhad Azad University, Mashhad, Iran https://orcid.org/0000-0001-9134-2660
  • Alireza Sarlak School of Medicine, Hamedan University, Hamedan, Iran https://orcid.org/0000-0001-9399-2552
  • Mohammadreza Eghbali School of Medicine, Hamedan University, Hamedan, Iran
  • Esmaeil Behzadi School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
  • Morteza Jafarinia Shiraz Neuroscience Research Center, Shiraz University of Medical Sciences, Shiraz, Iran https://orcid.org/0000-0002-3272-448X
Keywords: Multiple Sclerosis, Pregnancy, Disease-Modifying Treatments, Relapsing-remitting, Primary Progressive

Abstract

Women with multiple sclerosis (MS) of reproductive age are becoming pregnant at an alarmingly high rate. Disease control is required during the preconception, prenatal, and postpartum periods to reduce the likelihood of relapses of MS while minimizing hazards to the mother and fetus. It has long been understood that the disease activity of MS noticeably decreases in the third trimester of pregnancy, then noticeably increases in the first three months after delivery before returning to its pre-pregnancy baseline. Relapse during pregnancy and high rates of relapse before becoming pregnant have both been linked to an increased risk of postpartum attacks. In patients with relapse MS, recent results continue to support the notion that pregnancy does not affect long-term disease progression (and may even have the opposite effect); the situation is less clear for patients with progressive MS. It is comforting to know that none of the MS disease-modifying medications have been shown to cause teratogenic consequences. This review discusses the effects of pregnancy on disease activity and how to handle relapses when pregnant and breastfeeding.

References

Jafarinia M, Sadeghi E, Alsahebfosoul F, Etemadifar M, Jahanbani-Ardakani H. Evaluation of plasma Osteopontin level in relapsing-remitting multiple sclerosis patients compared to healthy subjects in Isfahan Province. Int J Neurosci. 2020;130(5):493-8.

https://doi.org/10.1080/00207454.2019.1694925

PMid:31795798

Parnell GP, Booth DR. The multiple sclerosis (MS) genetic risk factors indicate both acquired and innate immune cell subsets contribute to MS pathogenesis and identify novel therapeutic opportunities. Front Immunol. 2017;8:425.

https://doi.org/10.3389/fimmu.2017.00425

PMid:28458668 PMCid:PMC5394466

Jafarinia M, Amoon M, Javid A, Vakili S, Sadeghi E, Azadi D, et al. Male microchimerism in peripheral blood from women with multiple sclerosis in Isfahan Province. Int J Immunogenet. 2020;47(2):175-9.

https://doi.org/10.1111/iji.12465

PMid:31833227

Kyritsis AP, Boussios S, Pavlidis N. Cancer specific risk in multiple sclerosis patients. Crit Rev Oncol Hematol. 2016;98:29-34.

https://doi.org/10.1016/j.critrevonc.2015.10.002

PMid:26481954

Jafarinia M, Ashja-Arvan M, Hosseininasab F, Vakili S, Sadeghi E, Etemadifar M, et al. Evaluation of plasma soluble CD137 level in relapsing-remitting multiple sclerosis patients in comparison with healthy controls in Isfahan Province, Iran. Neurol Asia. 2020;25(3):361-5.

Cree BA. Multiple Sclerosis Therapy: Are We Ready for a One-Size-Fits-All Approach? J Neuroophthalmol. 2018;38(2):258-62.

https://doi.org/10.1097/WNO.0000000000000640

PMid:29750736

Langer-Gould A, Smith JB, Albers KB, Xiang AH, Wu J, Kerezsi EH, et al. Pregnancy-related relapses and breastfeeding in a contemporary multiple sclerosis cohort. Neurology. 2020;94(18):e1939-49.

https://doi.org/10.1212/WNL.0000000000009374

PMid:32284359 PMCid:PMC7274922

Bilbao MM, Durán SB, Llona JB, Rodriguez-Antigüedad A. Multiple sclerosis: pregnancy and women's health issues. Neurologia (English Edition). 2019;34(4):259-69.

https://doi.org/10.1016/j.nrleng.2016.06.014

Mansuori E, Alihemmati A, Mesbahi A. An overview on the effects of power frequency electromagnetic field exposure on the female reproduction system, pregnancy outcome and fetal development. J Med Chem Sci. 2020;3(1):60-70.

Voskuhl R, Momtazee C. Pregnancy: effect on multiple sclerosis, treatment considerations, and breastfeeding. Neurotherapeutics. 2017;14(4):974-84.

https://doi.org/10.1007/s13311-017-0562-7

PMid:28766273 PMCid:PMC5722767

Patas K, Engler JB, Friese MA, Gold SM. Pregnancy and multiple sclerosis: feto-maternal immune cross talk and its implications for disease activity. J Reprod Immunol. 2013;97(1):140-6.

https://doi.org/10.1016/j.jri.2012.10.005

PMid:23432880

Zenclussen AC. Adaptive immune responses during pregnancy. Am J Reprod Immunol. 2013;69(4):291-303.

https://doi.org/10.1111/aji.12097

PMid:23418773

Yamazaki S, Morita A. Dendritic cells in the periphery control antigen-specific natural and induced regulatory T cells. Front Immunol. 2013;4:151.

https://doi.org/10.3389/fimmu.2013.00151

PMid:23801989 PMCid:PMC3689032

Mor G, Cardenas I. The immune system in pregnancy: a unique complexity. Am J Reprod Immunol. 2010;63(6):425-33.

https://doi.org/10.1111/j.1600-0897.2010.00836.x

PMid:20367629 PMCid:PMC3025805

Coyle PK. Management of women with multiple sclerosis through pregnancy and after childbirth. Ther Adv Neurol Disord. 2016;9(3):198-210.

https://doi.org/10.1177/1756285616631897

PMid:27134675 PMCid:PMC4811012

Coyle PK, Oh J, Magyari M, Oreja-Guevara C, Houtchens M. Management strategies for female patients of reproductive potential with multiple sclerosis: an evidence-based review. Mult Scler Relat Disord. 2019;32:54-63.

https://doi.org/10.1016/j.msard.2019.04.003

PMid:31030020

Thöne J, Kollar S, Nousome D, Ellrichmann G, Kleiter I, Gold R, Hellwig K. Serum anti-Müllerian hormone levels in reproductive-age women with relapsing-remitting multiple sclerosis. Mult Scler. 2015;21(1):41-7.

https://doi.org/10.1177/1352458514540843

PMid:25145691

Nazari F, Shaygannejad V, Mohammadi Sichani M, Mansourian M, Hajhashemi V. Sexual dysfunction in women with multiple sclerosis: prevalence and impact on quality of life. BMC Urol. 2020;20(1):15.

https://doi.org/10.1186/s12894-020-0581-2

Al Abdali FH, Gowri V. The Etiology of Infertility and Treatment Outcome in Couples Aged 40 Years or more in a Non-IVF Setting. J Infertil Reprod Biol. 2021;9(2):87-92.

Ojoawo AO, Bamidele OO, Akinsomisoye SO, Adeyemi BA. Menstrual Period and Anthropometric Characteristics of Women with Secondary Infertility and Age Matched Control. J Infertil Reprod Biol. 2020;8(4):84-9.

Lengfeld J, Cutforth T, Agalliu D. The role of angiogenesis in the pathology of multiple sclerosis. Vascular Cell. 2014;6(1):1-6.

https://doi.org/10.1186/s13221-014-0023-6

PMid:25473485 PMCid:PMC4253611

Kaplan TB. Management of demyelinating disorders in pregnancy. Neurol Clin. 2019;37(1):17-30.

https://doi.org/10.1016/j.ncl.2018.09.007

PMid:30470273

Sintzel MB, Rametta M, Reder AT. Vitamin D and multiple sclerosis: a comprehensive review. Neurol Ther. 2018;7(1):59-85.

https://doi.org/10.1007/s40120-017-0086-4

PMid:29243029 PMCid:PMC5990512

Munger KL, Åivo J, Hongell K, Soilu-Hänninen M, Surcel H-M, Ascherio A. Vitamin D status during pregnancy and risk of multiple sclerosis in offspring of women in the Finnish Maternity Cohort. JAMA Neurol. 2016;73(5):515-9.

https://doi.org/10.1001/jamaneurol.2015.4800

PMid:26953778 PMCid:PMC4861670

Alwan S, Yee I, Dybalski M, Guimond C, Dwosh E, Greenwood T, et al. Reproductive decision making after the diagnosis of multiple sclerosis (MS). Mult Scler. 2013;19(3):351-8.

https://doi.org/10.1177/1352458512452920

PMid:22760102

Confavreux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P, Moreau T, Group PiMS. Rate of pregnancy-related relapse in multiple sclerosis. N Engl J Med. 1998;339(5):285-91.

https://doi.org/10.1056/NEJM199807303390501

PMid:9682040

Hughes SE, Spelman T, Gray OM, Boz C, Trojano M, Lugaresi A, et al. Predictors and dynamics of postpartum relapses in women with multiple sclerosis. Mult Scler. 2014;20(6):739-46.

https://doi.org/10.1177/1352458513507816

PMid:24107309

Fragoso YD, Boggild M, Macias-Islas MA, Carra A, Schaerer KD, Aguayo A, et al. The effects of long-term exposure to disease-modifying drugs during pregnancy in multiple sclerosis. Clin Neurol Neurosurg. 2013;115(2):154-9.

https://doi.org/10.1016/j.clineuro.2012.04.024

PMid:22633835

Nguyen A-L, Havrdova EK, Horakova D, Izquierdo G, Kalincik T, Van Der Walt A, et al. Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: a contemporary cohort study. Mult Scler Relat Disord. 2019;28:235-43.

https://doi.org/10.1016/j.msard.2019.01.003

PMid:30623864

Houtchens MK, Edwards NC, Schneider G, Stern K, Phillips AL. Pregnancy rates and outcomes in women with and without MS in the United States. Neurology. 2018;91(17):e1559-69.

https://doi.org/10.1212/WNL.0000000000006384

PMid:30266889 PMCid:PMC6205683

Moberg JY, Laursen B, Thygesen LC, Magyari M. Reproductive history of the Danish multiple sclerosis population: a register-based study. Mult Scler. 2020;26(8):902-11.

https://doi.org/10.1177/1352458519851245

PMid:31144565

Benoit A, Durand-Dubief F, Amato M-P, Portaccio E, Casey R, Roggerone S, et al. History of multiple sclerosis in 2 successive pregnancies: a French and Italian cohort. Neurology. 2016;87(13):1360-7.

https://doi.org/10.1212/WNL.0000000000003036

PMid:27466470

D'hooghe MB, Nagels G. Long-term effects of childbirth in MS. J Neurol Neurosurg Psychiatry. 2010;81(1):38-41.

https://doi.org/10.1136/jnnp.2008.163816

PMid:19939856

Zuluaga MI, Otero-Romero S, Rovira A, Perez-Hoyos S, Arrambide G, Negrotto L, et al. Menarche, pregnancies, and breastfeeding do not modify long-term prognosis in multiple sclerosis. Neurology. 2019;92(13):e1507-16.

https://doi.org/10.1212/WNL.0000000000007178

PMid:30824557 PMCid:PMC6453769

Runmarker B, Andersen O. Pregnancy is associated with a lower risk of onset and a better prognosis in multiple sclerosis. Brain. 1995;118(1):253-61.

https://doi.org/10.1093/brain/118.1.253

PMid:7895009

Ebers G, Yee I, Sadovnick A, Duquette P. Conjugal multiple sclerosis: Population‐based prevalence and recurrence risks in offspring. Ann Neurol. 2000;48(6): 927-31.

https://doi.org/10.1002/1531-8249(200012)48:6<927::AID-ANA14>3.0.CO;2-F

PMid:11117550

Fiddes B, Wason J, Kemppinen A, Ban M, Compston A, Sawcer S. Confounding underlies the apparent month of birth effect in multiple sclerosis. Ann Neurol. 2013;73(6):714-20.

https://doi.org/10.1002/ana.23925

PMid:23744589 PMCid:PMC3748787

Mirzaei F, Michels KB, Munger K, O'Reilly E, Chitnis T, Forman MR, et al. Gestational vitamin D and the risk of multiple sclerosis in offspring. Ann Neurol. 2011;70(1):30-40.

https://doi.org/10.1002/ana.22456

PMid:21786297 PMCid:PMC3205990

Riley M, Dobson M, Jones E, Kirst N. Health maintenance in women. Am Fam Physician. 2013;87(1):30-7.

Paavilainen T, Kurki T, Färkkilä M, Salonen O, Parkkola R, Airas L. Lower brain diffusivity in postpartum period compared to late pregnancy: results from a prospective imaging study of multiple sclerosis patients. Neuroradiology. 2012;54(8):823-8.

https://doi.org/10.1007/s00234-011-0994-4

PMid:22160148

Ponsonby A-L, Lucas R, Van Der Mei I, Dear K, Valery P, Pender M, et al. Offspring number, pregnancy, and risk of a first clinical demyelinating event: the AusImmune Study. Neurology. 2012;78(12):867-74.

https://doi.org/10.1212/WNL.0b013e31824c4648

PMid:22402857

Lebrun C, Le Page E, Kantarci O, Siva A, Pelletier D, Okuda D, et al. Impact of pregnancy on conversion to clinically isolated syndrome in a radiologically isolated syndrome cohort. Mult Scler. 2012;18(9):1297-302.

https://doi.org/10.1177/1352458511435931

PMid:22300971

Krysko KM, Bove R, Dobson R, Jokubaitis V, Hellwig K. Treatment of women with multiple sclerosis planning pregnancy. Curr Treat Options Neurol. 2021;23(4):1-19.

https://doi.org/10.1007/s11940-021-00666-4

PMid:33814892 PMCid:PMC8008016

Neuhaus O, Kieseier BC, Hartung H-P. Pharmacokinetics and pharmacodynamics of the interferon-betas, glatiramer acetate, and mitoxantrone in multiple sclerosis. J Neurol Sci. 2007;259(1-2):27-37.

https://doi.org/10.1016/j.jns.2006.05.071

PMid:17391705

Hellwig K, Geissbuehler Y, Sabidó M, Popescu C, Adamo A, Klinger J, et al. Pregnancy outcomes in interferon-beta-exposed patients with multiple sclerosis: results from the European Interferon-beta Pregnancy Registry. J Neurol. 2020;267(6):1715-23.

https://doi.org/10.1007/s00415-020-09762-y

PMid:32100126 PMCid:PMC7293672

Hakkarainen KM, Juuti R, Burkill S, Geissbühler Y, Sabidó M, Popescu C, et al. Pregnancy outcomes after exposure to interferon beta: a register-based cohort study among women with MS in Finland and Sweden. Ther Adv Neurol Disord. 2020;13:1756286420951072.

https://doi.org/10.1177/1756286420951072

PMid:33101459 PMCid:PMC7549181

Hale TW, Siddiqui AA, Baker TE. Transfer of interferon β-1a into human breastmilk. Breastfeed Med. 2012;7(2):123-5.

https://doi.org/10.1089/bfm.2011.0044

PMid:21988602

Ciplea AI, Langer-Gould A, Stahl A, Thiel S, Queisser-Wahrendorf A, Gold R, et al. Safety of potential breast milk exposure to IFN-β or glatiramer acetate: one-year infant outcomes. Neurol Neuroimmunol Neuroinflamm.

;7(4):e757.

Cassina M, Johnson D, Robinson L, Braddock S, Xu R, Jimenez J, et al. Pregnancy outcome in women exposed to leflunomide before or during pregnancy. Arthritis Rheum. 2012;64(7):2085-94.

https://doi.org/10.1002/art.34419

PMid:22307734

Correale J, Abad P, Alvarenga R, Alves-Leon S, Armas E, Barahona J, et al. Management of relapsing-remitting multiple sclerosis in Latin America: Practical recommendations for treatment optimization. J Neurol Sci. 2014;339(1-2):196-206.

https://doi.org/10.1016/j.jns.2014.02.017

PMid:24607335

Buraga I, Popovici RE. Multiple sclerosis and pregnancy: current considerations. Scientific World Journal. 2014;2014:513160.

https://doi.org/10.1155/2014/513160

PMid:24977202 PMCid:PMC3997075

Varytė G, Arlauskienė A, Ramašauskaitė D. Pregnancy and multiple sclerosis: an update. Curr Opin Obstet Gynecol. 2021;33(5):378.

https://doi.org/10.1097/GCO.0000000000000731

PMid:34310364 PMCid:PMC8452312

Bodiguel E, Bensa C, Brassat D, Laplaud D, Le Page E, Ouallet J-C, et al. Multiple sclerosis and pregnancy. Rev Neurol (Paris). 2014;170(4):247-65.

https://doi.org/10.1016/j.neurol.2013.09.010

PMid:24684929

Karlsson G, Francis G, Koren G, Heining P, Zhang X, Cohen JA, et al. Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis. Neurology. 2014;82(8):674-80.

https://doi.org/10.1212/WNL.0000000000000137

PMid:24463630 PMCid:PMC3945658

Lu E, Wang BW, Guimond C, Synnes A, Sadovnick AD, Dahlgren L, et al. Safety of disease-modifying drugs for multiple sclerosis in pregnancy: current challenges and future considerations for effective pharmacovigilance. Expert Rev Neurother. 2013;13(3):251-61.

https://doi.org/10.1586/ern.13.12

PMid:23448215

Landi D, Portaccio E, Bovis F, Annovazzi P, Morra V, Bucello S, et al. Continuation of natalizumab versus interruption is associated with lower risk of relapses during pregnancy and postpartum in women with MS. Mult Scler. 2019;25:892-4.

Dobson R, Dassan P, Roberts M, Giovannoni G, Nelson-Piercy C, Brex PA. UK consensus on pregnancy in multiple sclerosis:'Association of British Neurologists' guidelines. Pract Neurol. 2019;19(2):106-14.

https://doi.org/10.1136/practneurol-2018-002060

PMid:30612100

Friend S, Richman S, Bloomgren G, Cristiano LM, Wenten M. Evaluation of pregnancy outcomes from the Tysabri®(natalizumab) pregnancy exposure registry: a global, observational, follow-up study. BMC Neurol. 2016;16(1):1-9.

https://doi.org/10.1186/s12883-016-0674-4

PMid:27552976 PMCid:PMC4995778

Haghikia A, Langer-Gould A, Rellensmann G, Schneider H, Tenenbaum T, Elias-Hamp B, Menck S, Zimmermann J, Herbstritt S, Marziniak M, Kümpfel T, Meinl I, Plavina T, Gold R, Hellwig K. Natalizumab use during the third trimester of pregnancy. JAMA Neurol. 2014;71(7):891-5.

https://doi.org/10.1001/jamaneurol.2014.209

PMid:24821217

Alroughani R, Altintas A, Al Jumah M, Sahraian M, Alsharoqi I, AlTahan A, et al. Pregnancy and the Use of Disease-Modifying Therapies in Patients with Multiple Sclerosis: Benefits versus Risks. Mult Scler Int. 2016;2016:1034912.

https://doi.org/10.1155/2016/1034912

PMid:28078140 PMCid:PMC5203912

Simone IL, Tortorella C, Ghirelli A. Influence of Pregnancy in Multiple Sclerosis and Impact of Disease-Modifying Therapies. Front Neurol. 2021;12:697974.

https://doi.org/10.3389/fneur.2021.697974

PMid:34276545 PMCid:PMC8280312

Decallonne B, Bartholomé E, Delvaux V, D'haeseleer M, El Sankari S, Seeldrayers P, et al. Thyroid disorders in alemtuzumab-treated multiple sclerosis patients: a Belgian consensus on diagnosis and management. Acta Neurol Belg. 2018;118(2):153-9.

https://doi.org/10.1007/s13760-018-0883-2

PMid:29372482 PMCid:PMC5971042

Rehman N, Ghotekar S, Izharullah M, Zaheer J, Akram M, Khan M. Prevalence and Treatment of Hypertension in District Bhimber, Azad Jammu and Kashmir. J Med Chem. 2021;4(1):75-83.

Moreno Torres I, García-Merino A. Anti-CD20 monoclonal antibodies in multiple sclerosis. Expert Rev Neurother. 2017;17(4):359-71.

https://doi.org/10.1080/14737175.2017.1245616

PMid:27718747

Chakravarty EF, Murray ER, Kelman A, Farmer P. Pregnancy outcomes after maternal exposure to rituximab. Blood. 2011;117(5):1499-506.

https://doi.org/10.1182/blood-2010-07-295444

PMid:21098742

Giovannoni G, Galazka A, Schick R, Leist T, Comi G, Montalban X, et al. Pregnancy outcomes during the clinical development program of cladribine in multiple sclerosis: an integrated analysis of safety. Drug Saf. 2020;43(7):635-43.

https://doi.org/10.1007/s40264-020-00948-x

PMid:32447743 PMCid:PMC7305061

Milad S, Ehsan J, Farzad MS, Mohsen R, Ahmad B, Shahram M, et al. Effects of Dimethyl Fumarate on the Karnofsky Performance Status and Serum S100β Level in Newly Glioblastoma Patients: A Randomized, Phase-II, Placebo, Triple Blinded, Controlled Trial: Effect of DMF On the Serum S100β Level and KPS Score of GBM Patients. GMJ. 2022;10:1-10.

Hellwig K, Rog D, McGuigan C, Houtchens MK, Bruen DR, Mokliatchouk O, et al. Interim Analysis of Pregnancy Outcomes After Exposure to Dimethyl Fumarate in a Prospective International Registry. Neurol Neuroimmunol Neuroinflamm. 2021;9(1):e1114.

https://doi.org/10.1212/NXI.0000000000001114

PMid:34815321 PMCid:PMC8611504

Miller DH, Fazekas F, Montalban X, Reingold SC, Trojano M. Pregnancy, sex and hormonal factors in multiple sclerosis. Mult Scler. 2014;20(5):527-36.

https://doi.org/10.1177/1352458513519840

PMid:24446387 PMCid:PMC5458871

Pakpoor J, Disanto G, Lacey MV, Hellwig K, Giovannoni G, Ramagopalan SV. Breastfeeding and multiple sclerosis relapses: a meta-analysis. J Neurol. 2012;259(10):2246-8.

https://doi.org/10.1007/s00415-012-6553-z

PMid:22619059

Hellwig K. Pregnancy in multiple sclerosis. Eur Neurol. 2014;72(Suppl 1):39-42.

https://doi.org/10.1159/000367640

PMid:25278125

Haas J, Hommes OR. A dose comparison study of IVIG in postpartum relapsing-remitting multiple sclerosis. Mult Scler. 2007;13(7):900-8.

https://doi.org/10.1177/1352458506075654

PMid:17881400

Published
2022-12-31
How to Cite
Badali, A., GhorbaniNia, R., Mohammadian, S., poudineh, S., Sarlak, A., Eghbali, M., Behzadi, E., & Jafarinia, M. (2022). Multiple sclerosis impact on pregnancy: An update on management issues. Galen Medical Journal, 11, e2703. https://doi.org/10.31661/gmj.v11i.2703
Section
Review Article